Summary of Oral Arguments in AMP v. USPTO remand
| July 20, 2012
July 20, 2012
In the immortal words of baseball great Yogi Berra, “It’s déjà vu all over again”. A little more than a year after they previously heard AMP v. USPTO, the CAFC panel of Judges Lourie, Bryson and Moore have once again taken up the question of whether isolated DNA and related methods are patent eligible subject matter under 35 U.S.C. §101.
Tags: §101 > bilski > biotech > diagnostics > DNA > law of nature > Mayo > Myriad > patent eligible subject matter
USPTO issues Interim Procedure for §101 examination after Prometheus v. Mayo
| July 3, 2012
Since the Supreme Court issued their decision in Mayo v. Prometheus (English discussion here; Japanese discussion here), rejections of claims based on failure to comply patent-eligible subject matter requirements of §101 seem to be on the rise. Until now, Examiners had been given only very little guidance (see here), resulting in Mayo being cited inconsistently. However, today, the USPTO has provided Examiners with additional guidance about how to handle this issue. Please click below for more information:
These guidelines should improve consistency of the manner in which Mayo and related cases are relied upon by the Examining Corps, as well as provide practitioners with a basic framework for responding to such rejections.
Keep in mind that as the CAFC (and perhaps the Supreme Court, eventually) continues to address this issue in other pending cases such as Myriad and Ultramercial, these guidelines may be revised by the USPTO.
Tags: §101 > bilski > law of nature > Mayo > Myriad > patent eligible subject matter
